A recently study of rimegepant, an investigational oral calcitonin gene–related peptide receptor (CGRP) blocker for migraine, resulted in a higher percentage of patients relieved of pain over placebo.
A recent study of rimegepant, an investigational oral calcitonin gene—related peptide receptor (CGRP) blocker for migraine, resulted in a higher percentage of patients relieved of pain over placebo. The results were published in the New England Journal of Medicine this month.
The study was led by researchers at Albert Einstein College of Medicine and Montefiore Health System.
In the multicenter, double-blind, phase 3 trial, adults with at least a 1-year history of migraine and 2 to 8 migraine attacks of moderate or severe intensity per month were randomized to receive rimegepant orally at a dose of 75 mg, or matching placebo, for the treatment of a single migraine attack.
Two hours after patients took the dose of rimegepant or placebo, they were assessed for 2 end points: pain relief, and freedom from their most bothersome symptom, other than pain. Participants chose their most bothersome symptom from a list, including intolerance to light, intolerance to loud sounds, or nausea.
The study included 1186 patients; 594 received rimegepant and 594 received placebo. Of those, 537 patients in the rimegepant group and 535 patients in the placebo group could be evaluated.
The overall mean age of the patients evaluated for efficacy was 40.6 years, and 88.7% were women.
In a modified intention-to-treat analysis, the percentage of patients who were pain-free 2 hours after receiving the dose was 19.6% in the rimegepant group and 12.0% in the placebo group (absolute difference, 7.6 percentage points; 95% confidence interval [CI], 3.3 to 11.9; P <.001).
The percentage of patients who were free from their most bothersome symptom 2 hours after the dose was 37.6% in the rimegepant group and 25.2% in the placebo group (absolute difference, 12.4 percentage points; 95% CI, 6.9 to 17.9; P <.001). The most common adverse events were nausea and urinary tract infection.
The study had a few limitations. There was no active comparator to rimegepant. Second, the assessment of the drug’s effect on a single attack did not permit assessment of the consistency of the drug on multiple effects over time in the same patient. Lastly, it is not known how the drug would perform in patients with cardiovascular disease.
All authors have a financial relationship with the drugmaker, which funded the study.
Reference
Lipton RB, Croop R, Stock EG, et al. Rimegepant, an oral calcitonin gene—related peptide receptor antagonist, for migraine. N Engl J Med. 2019; 381:142-149. doi: 10.1056/NEJMoa1811090.
Optimizing Episodic Migraine Care: ACP’s Latest Treatment Guidance
February 3rd 2025With historical data showing migraine to be underdiagnosed and undertreated, new guidance from the American College of Physicians (ACP) encompasses 3 recommendations on treating episodic migraine in adult patients in the outpatient setting.
Read More
Update on Migraine Patient Care Challenges During the Pandemic
October 5th 2021Migraines plague some 35 million Americans, the majority of them women in their 30s and 40s, and disabling pain and symptoms are linked to lost productivity at work, school, and home. On this episode of Managed Care Cast, we bring you an excerpt of an interview with a headache specialist about the extra challenges for patients and providers during the pandemic.
Listen
Care for Migraine Insufficient in Germany, Online Survey Finds
March 25th 2022An online survey of migraineurs in Germany aimed to evaluate their most pressing unmet needs, with data collected on socioeconomic background, medical care experience, acute medication use, and migraine prophylaxis use and experience.
Read More
CGRP Inhibitors: A Promising New Class of Drugs for Migraine
November 14th 2018This fall, The American Journal of Managed Care® convened a panel of experts on migraine to discuss calcitonin gene-related peptide (CGRP) inhibitors, an emerging therapy for the condition, which affects 39 million people in the United States.
Listen